The investigational drug is an injectable recombinant humanized anti-BCMA/CD3 bispecific antibody (code: F182112) that can simultaneously target the immune effector cell antigen CD3 and the antigen BCMA. Through a dual-targeting mechanism, it aims to guide the body's own immune system to target and kill B cells and plasma cells that overexpress BCMA.Based on the application of B cell depletion strategies in the treatment of autoimmune diseases, as well as the exploration of similar drugs in autoimmune diseases, we speculate that F182112 is also effective for autoimmune diseases. Therefore, we plan to carry out clinical research of F182112 in patients with systemic lupus erythematosus, with the aim of bringing more treatment options to patients.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
64
F182112 Dose Escalation and Dose Expansion
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
RECRUITINGThe Incidence of Adverse Events (AE), Serious Adverse Events (SAE)
Time frame: During the period of dose-limiting toxicity observation (within 28 days after the first administration)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.